Abstract: There are provided in accordance with the present invention crystalline forms A, B, C, F, G, I, J, P, and Q of efaproxiral sodium. Also provided is the amorphous form of efaproxiral sodium. Also provided are methods of forming the novel polymorphs and the amorphous form of efaproxiral sodium, therapeutic methods utilizing them and pharmaceutical dosage forms containing them.

Abstract: The present invention relates to polymorphic forms of (S)-tetrahydrofuran-3-yl 3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate, processes therein, pharmaceutical compositions thereof, and uses therewith.

Abstract: The present invention provides co-complexes of enterostatin that can display advantageous hygroscopicity, advantageous stability, or both. The co-complexes of enterostatin can be useful for the manufacture of an pharmaceutical product comprising enterostatin.

Abstract: Salt forms of potent modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.

Abstract: Crystal form F of [2S, 4R, 5R, 8R, 9S, 10S, 11R, 12R]-9-[(2,6-dideoxy-3-C-methyl-3-O-methyl-?-L-ribo-hexopyranosyl)oxy]-5-ethyl-4-methoxy-2,4,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(isopropylmethylamino)-?-D-xylo-hexopyranosyl]oxy]-6,15-dioxabicyclo[10.2.1]pentadec-14(1)-ene-3,7-dione (E)-2-butenedioic acid salt (2:1) showing strong X-ray diffraction peaks at diffraction angles 2?=6.6° and 8.5°, Crystal form D anhydrate of said compound showing strong X-ray diffraction peaks at diffraction angles 2?=7.1°, 13.5° and 14.2°, Crystal form D X-hydrate of said compound showing strong X-ray diffraction peaks at diffraction angles 2?=7.1° and 14.2° but not showing a strong X-ray diffraction peak at a diffraction angle 2?=13.5°, Solvate Crystal forms G1, G2 and G3 of said compound characterized by 2-theta angle positions in the powder X-ray diffraction pattern of 5.4°, 10.4°, 10.7° and 12.1°.